This monthly newsletter delivers the best in news, project spotlights, events, and more directly to your inbox every month. See what's been happening so far this month...
This scheme is for early career researchers and innovators who are either:
We are offering funding to support ambitious research or innovation programmes across UKRI’s remit.
You must be based at, and have the support of, an eligible academic or non-academic institution.
There is no minimum or maximum award value.
Your project can last for up to four years, with the option to apply to renew for a further three years.
Today we’re launching brand new research with @warwickuni@johnmacartney, exploring the impact of Covid-19 on hospices and what this means for the future of hospice care.
Welcome to the May WMAHSN Update
We have a new-look newsletter to bring you the best in news, project spotlights, events, and more. See what's coming up in May...
Understanding how to stop ice growth with amino acids
The GibsonGroup, working with the Sosso Group in chemistry have demonstrated that simple amino acids can slow the recrystallisation of ice. Ice recrystallisation inhibition (IRI) is normally associated with ice binding proteins, but the team show that amino acids can also achieve this. Using a combination of experiments and modelling the importance of the structure of the amino acid is explored, and the relative role of ice binding investigated.
Read the paper here.
Multiple sclerosis mystery solved: Glandular fever virus is the cause.
Monash Warwick Alliance antimicrobial resistance (AMR) training programme in Emerging Superbug Threats – Call for Research Fellow Mentors
Academic colleagues are invited to apply to become a mentor for a philanthropically funded research fellow associated with this programme, which aims to deliver interdisciplinary AMR research training across the Warwick and Monash campuses to recent PhD graduates with relevant expertise. Further information about the goals and structure of the programme, and details of how to apply can be found here https://warwick.ac.uk/global/partnerships/mwa/current/amr/. The deadline for submitting applications is 28 Feb 2022.
Lighting Up Tumour Treatments
The Perrier Lab have just published a new study in Angewandte Chemie which shows how polymeric nanotubes can be designed to switch their fluorescence on as they deliver a commercial anticancer drug (doxorubicin), thereby permitting the in-situ visualization of drug release. By this method, we can both treat a cancer tumour and show where the tumour is located. These theranostic systems (from therapeutic and diagnostic) form a new approach to drug delivery.
Read the paper here.
2021 may not have been the year anyone expected, with COVID-19 still making its presence known in our lives and around the world.
But a lot of progress has still been made. From promising new cancer drugs to trialling a cancer blood test, here are some of the top good news stories from the year.
More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence (NICE).
The drug will now be available to people with early-stage non small cell lung cancer (NSCLC) who have had surgery to remove their tumour that has errors in a gene called EGFR.
Welcome to November's AHSN Funding Newsletter. This bulletin alerts you to funding opportunities, international opportunities, events and other relevant AHSN news. For each opportunity we have provided a brief summary and a link to full details.
How insulin has changed diabetes care, 100 years on
Dr Thomas Barber was interviewed by Medical News Today on current insulin research and potential future developments. Listen to the interview here.
The fund aims to strengthen or initiate exchange between Warwick researchers/educators and their counterparts from leading international universities or institutes by enabling them to jointly undertake preliminary research, organize meetings, conferences, or workshops.
Immunotherapy combination could be alternative to ‘Extreme’ chemotherapy in some head and neck cancers
An immunotherapy combination could be better than standard ‘Extreme’ chemotherapy as first-line treatment for some patients with relapsed or metastatic head and neck cancer, or both, a major phase III trial suggests.
A new drug to lower cholesterol which was appraised by Warwick Evidence will be made available to hundreds of thousands of NHS patients